Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL

MONITORING OF MEDICINE THERAPY IN DM (Diabetes Mellitus) PATIENTS, MELENA, ANEMIA, HIPOALBUMIN AND SEPSIS IN HOSPITAL “ X ” sari, dini permata
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 8, No 2 (2023)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v8i2.6807

Abstract

Diabetes Mellitus (DM) is a group of chronic metabolic diseases with hyperglycemia characteristics, this disease can attack several organs of the body causing various complaints. Diabetes Mellitus (DM) is a disease characterized by blood sugar levels. Physical activity is any body movement produced by skeletal muscles that requires energy. Lack of physical activity is an independent risk factor for chronic disease. This study aims to determine the effect of physical activity on blood sugar levels in patients with diabetes mellitus. Sepsis is the invasion of pathogenic microorganisms or their toxins into the blood or other tissues, resulting in an exaggerated systemic response to infection, which causes a collection of clinical symptoms and ends in a life-threatening state of organ dysfunction. Anemia is indeed not a direct complication caused by Type 2 DM, but in patients with diabetes, diabetes can damage blood vessels in the body and can cause kidney problems in the long term if not controlled. Impaired kidney function can cause anemia. Melena is a condition when the stool becomes dark or black in color, which is caused by bleeding in the upper gastrointestinal tract. Hypoalbuminemia in critical illness is an important marker of mortality. The pathophysiology of hypoalbuminemia in critical illness including decrease of production, inflammation marker, vascular leakage, and malnutrition. Administration of intravenous human albumin is needed to be considered for treatment of hypoalbuminemia in critical illness.This report was conducted to find out drug related problems (DRP's) in the treatment management of DM (Diabetes Melius) Patients, Melena Anemia, Hipoalbumin and Sepsis at “ X “ Hospital. The patient on behalf of Mrs.R.M was treated in the inpatient room. Drug Therapy Monitoring to ensure rational use of drugs, so that unwanted events do not occur. 
DRUG THERAPY IN PATIENTS WITH GRADE 4 DEXTRA HIP OSTEOARTHRITIS WITH COMORBID HYPERTENSION AND TYPE 2 DIABETES MELLITUS Astiani, Rangki; Piter, Piter; Anggraeni, Ria; Luthfiana, Farisa; Sari, Dini Permata; Ramatillah, Diana Laila; Khan, Khasif
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 10, No 2 (2025)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v10i2.8977

Abstract

Osteoarthritis (OA) is a chronic degenerative disease that affects the joints, especially heavy joints such as the knees and hips. OA often causes chronic pain and limited mobility, which is even more complex when accompanied by comorbid hypertension and type 2 diabetes mellitus. These comorbidities increase the risk of pharmacotherapy side effects and drug interactions, requiring a multidisciplinary approach and careful clinical pharmacy monitoring. The purpose of this report is to review the pharmacotherapy management of grade 4 OA Hip Dextra with comorbid HT and DMT2, assessing the safety, effectiveness, and role of clinical pharmacists in therapy optimization. A retrospective case study was conducted by analyzing the patient's medical records, including anamnesis, physical examination, laboratory, pharmacological therapy, and clinical response. The analysis was conducted based on the national guidelines of the Indonesian Ministry of Health, the 2021 National Formulary, PERKENI 2023, and PAPDI 2021. The patient was given combination therapy of NSAIDs, analgesics, prophylactic antibiotics, muscle relaxants, gastric protection, and supplementation for anemia. Therapeutic adjustments were made according to the patient's response and laboratory parameters. Clinical pharmacy monitoring ensures pain control, mobility, hemoglobin, and blood sugar. A multidisciplinary approach based on national guidelines has been shown to improve the safety and effectiveness of OA therapy with multiple comorbidities.